I completed my MSc. in medical biotechnology from AIIMS, New delhi, India during which I studied the host-pathogen interaction in infections caused by Mycobacterium. I obtained my PhD in 2016 from Jawaharlal Nehru University, New Delhi India. My PhD mainly focussed on understanding the immunobiology of a parasitic disease called leishmaniasis with an aim to develop novel therapeutics against the parasite. Before joining Prof. Rabbitts group I was working as a postdoc in Dr. Matthew Reeves and Prof. Greg Towers group at University college London. Here I was interested in identifying and characterizing the antiviral activity of novel small molecule inhibitors targeting the host protein Cyclophillin-A. I joined Prof. Rabbitts group in October 2017 and my work here will focus on utilizing and developing methodologies to target protein-protein interactions using antibody fragments.
I did my undergraduate in Organic Chemistry at the University of Rouen and obtained my PhD on permanganate oxidative cyclisation under the supervision of Dr R.C.D. Brown at the University of Southampton. I then undertook two consecutive post-doctoral positions with Professor T.J. Donohoe on tethered aminohydroxylation methodology and with Dr J.M. Brown on resolution of stereolabile biaryl ligands using novel chiral dienes at the Chemistry Research Laboratory, Oxford.
I previously worked as a senior post-doctoral researcher for Dr A.J. Russell and Professor S.G. Davies, at Oxford. I had the opportunity to work on a range of medicinal chemistry projects from synthesizing novel PIM kinase inhibitors used in the treatment of cancer, to anti-viral agents against Hepatitis C virus as well as novel compounds used in the proliferation of stem cells and their selective differentiation.
I am currently working with Professor TH Rabbitts and Dr. AJ Russell on the synthesis of novel chiral small molecules, used in protein-protein interaction to prevent, proliferation of cancer cells via a fragment-based approach and insilico methods using inhibition antibody fragments as structured templates.
I completed my MSc degrees in Biochemistry and Oncology at the INSA Toulouse and at the Paul Sabatier University in Toulouse, France. I started my PhD. in 2010 in Professor Gilles Favre's group in Toulouse. My PhD. focused on two linked parts: the characterisation of a universal synthetic humanised nanobody library and the establishment of an in-cell screening method that reveals functional intrabodies using the fusion Fbox domain-nanobodies. Applying this screen, we were able to get an Fbox-intrabody able to degrade selectively the small GTPase RHOB-GTP. I was awarded my PhD. in 2014 and I continued my work on this project until I joined Professor Rabbitts' group in April 2015. My work here will focus on the development of in-cell based assays for screening of small molecules / peptides inhibitors of LMO2 / VH interaction.
I joined Prof. Rabbitts’ group as Research Assistant in 2006 after completing my BSc in Biochemistry at the University of Leeds. I play a varied role in the lab, covering a wide range of laboratory techniques. I am currently working on projects related to LMO2 function in T-ALL and development of methods to assist antibody fragments in the therapeutic setting. In October 2014 I started working for a DPhil.
Arvind Kumar Jain
I come from Pharmaceutical Sciences background, pursued B.Pharm from Devi Ahilya University Indore and M.Pharm from Dr HS Gour University Sagar, India. I did my M.Pharm. thesis project with Prof SP Vyas; where I developed diblock and triblock (ABA & BAB) copolymeric nanoparticles of PLA & PEG evaluating their efficiency to serve as a single dose mucosal vaccine delivery system, encapsulating subunit antigens. Before joining the PhD I had chance to work as project associate in one of the premier institute of India, Indian Institute of Technology Kanpur with Prof DS Katti. Here my project involved synthetic modification of a natural polysaccharide enabling its formulation to microparticles using electrospraying technique to serve as an efficient colon targeted drug delivery system. Continuing my research career I joined PhD in Drug Delivery at the Queens University Belfast, UK with Dr VL Kett. My Phd project aimed development of a freeze-dried polymeric nanoparticulate system that can cross the ocular barriers allowing gene delivery to the posterior eye for the management of Retinopathy of prematurity. The project also involved studying the influence of physicochemical factors on DNA condensation using a novel cationic peptide, developed in one of my co-supervisors Dr HO McCarthy’s lab.
I joined Prof Rabbitts’s lab as a Postdoctoral Scientist in April 2014 and my work here is focused on the development of various targeted nanoparticulate systems for the intracellular delivery of antibody fragment vectors leading to intervention of protein-protein interactions at subcellular level especially cancer associated oncogenic protein interactions.
I joined the WIMM in September 2012 as PA to Professor Rabbitts. Before joining the WIMM I worked at BBC magazines in the production department for 8 years overseeing the print, buying and production of a portfolio of titles including Lonely Planet Traveller, Dr. Who Adventures and Top of the Pops.
I completed my MSc degree in molecular biology and biochemistry in 2012 at Toulouse University (France). I received my PhD in biochemistry in 2016 from Marseille University (France). During my PhD I worked on the evaluation of a chemical library dedicated to protein-protein interactions inhibition and on the study of the interaction between two proteins implicated in dengue virus replication.
I joined Prof. Rabbitts group at the WIMM in January 2017 and now work on the development of technologies for protein protein interactions inhibitions by antibody fragments.
I completed a Biochemistry degree with an integrated Masters at the University of Bath, during which I worked at St Jude Children’s Research Hospital, Memphis, TN, investigating small molecule inhibitors targeting the Wnt receptor Frizzled. I received my PhD in Structural Immunology from University College London having worked in Prof. Perkins group studying protein-carbohydrate interactions of the complement system.
Following my PhD I worked as a life science editor before undertaking a post-doctoral position in protein crystallography with Prof. Acharya at the University of Bath. I joined Prof. Rabbitts group at the WIMM in August 2015 and now work on the development of methodologies for targeting protein-protein interactions and for studying chromosomal translocations in cancer.
I joined Professor Rabbitts group as the Project Manager of his Wellcome Trust SDDI award in 2013. The aim of the SDDI project is to identify small molecule candidates capable of inhibiting or interfering with intracellular protein-protein interactions, especially cancer associated oncogenic protein interactions and using antibody fragments as structural templates.
Prior to this appointment, I undertook a post-doctoral research position under the supervision of Professor Steve Davies and Dr Angela Russell at the Chemistry Research Laboratory, Oxford (2008 – 2013). During my post-doctoral research, I had the opportunity to work on a broad range of medicinal chemistry projects varying from the synthesis of novel PIM kinase inhibitors, to anti-viral agents against Hepatitis C virus as well as Protein Methyl Transferase inhibitors (PRMT). I obtained my PhD in Organic Chemistry at The Institute of Cancer Research under the supervision of Dr Edward McDonald and Professor Julian Blagg, working on Protein Kinases and Wnt pathway inhibitors. My interest in chemistry came after I graduated as BSc at Kings College London where I also undertake an MSc in synthetic chemistry.
I graduated from Nanjin University of Technology (China) in 2006 with BEng degree in Pharmaceutical Engineering before I came to UK. I completed my PhD in July 2012 in Professor Jon Sayers’ group in the University of Sheffield where I studied the mechanism of structural specific endo/exo-nuclease. I moved to Oxford in September 2012 in Professor Terence Rabbitts’ group and I am now working on protein-protein interactions in cancer and methods for drug delivery.